Monthly IV drug aims to slash infection risk in blood cancer patients

NCT ID NCT07582432

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This study tests whether a monthly IV infusion of Gamunex-C, given alongside standard medical care, can reduce serious infections in people with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma. About 49 participants will receive 13 doses over one year. The main goal is to see how many serious bacterial infections occur per person per year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA, MULTIPLE MYELOMA, OR NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Study Site 101

    RECRUITING

    Fort Wayne, Indiana, 46894, United States

    Contact Email: •••••@•••••

  • Study Site 102

    NOT_YET_RECRUITING

    St. Petersburg, Florida, 33709, United States

    Contact Email: •••••@•••••

  • Study Site 103

    NOT_YET_RECRUITING

    Tacoma, Washington, 98405, United States

    Contact Email: •••••@•••••

  • Study Site 104

    NOT_YET_RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

  • Study Site 105

    NOT_YET_RECRUITING

    Westbrook, Maine, 04092, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.